FDA Approves First-Ever Stent for Debilitating Brain Pressure Disorder

HARRISON, N.Y. – March 31, 2026 – In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval for the first-ever medical device specifically designed to treat severe cases of a debilitating neurological condition that has long frustrated patients and physicians alike. Serenity Medical announced today that its River™ stent has received a Humanitarian Device Exemption (HDE), clearing its use for adults with severe idiopathic intracranial hypertension (IIH) who have not found relief from other therapies.

The approval marks a pivotal moment for a patient population, predominantly women aged 20 to 50, who suffer from the chronic headaches, vision loss, and cognitive impairment caused by elevated pressure inside the skull. For years, treatment options for the most severe cases were limited to high-risk shunting surgeries or the off-label use of stents not designed for the brain's delicate venous anatomy. The River stent is the first purpose-built, FDA-approved tool engineered to address this specific challenge.

“Delivering the first venous stent approved for severe, refractory IIH is incredibly meaningful to our dedicated team and to people living with IIH who have had limited options for relief until now,” said Y. Pierre Gobin, MD, Founder of Serenity Medical and a neurointerventional expert at Weill-Cornell Medicine. “Our company was founded with the goal of addressing a problem that has long perplexed the medical community and caused debilitating symptoms in the women suffering with it.”

A Lifeline for a Debilitating Condition

Idiopathic intracranial hypertension is a perplexing disorder where the body produces too much cerebrospinal fluid (CSF) or does not absorb it properly, leading to a dangerous buildup of pressure around the brain. While its exact cause is unknown, it is strongly linked to obesity, and its incidence has been rising in tandem with global obesity rates. Sufferers often describe a constant, disabling headache, pulsatile tinnitus (a rhythmic whooshing sound in the ears), and progressive vision loss that can lead to permanent blindness.

First-line treatments include weight loss and medications like acetazolamide to reduce CSF production. However, a significant subset of patients are considered “refractory,” meaning their symptoms persist or worsen despite these measures. For them, the path forward has been fraught with difficult choices.

Surgical options have traditionally included CSF shunts, which divert fluid from the brain to the abdomen. While effective at reducing pressure, these shunts have notoriously high complication and failure rates, often requiring multiple revision surgeries over a patient’s lifetime. Another option, optic nerve sheath fenestration, can help save vision but does not address the underlying pressure or the associated headaches. In recent years, some specialists have turned to the off-label use of cardiovascular stents to open narrowed venous sinuses in the brain, a common finding in IIH patients. However, these devices were not engineered for the unique environment of the cerebral veins, raising concerns about safety and long-term effectiveness.

The River stent’s approval directly confronts this unmet need, providing a validated option for a specific patient group: adults with severe headaches who have failed six months of medical therapy, or those whose vision is threatened despite treatment.

The Science and Strategy Behind the Approval

The FDA’s decision was based on the results of The River Study, a prospective, multi-center trial published in the Journal of Neurointerventional Surgery in February 2025. The study enrolled 39 subjects across five U.S. centers, representing the first major trial of a venous stent specifically designed for IIH. The one-year results were compelling, meeting the primary safety endpoint with a major adverse event rate of just 5.4%. Furthermore, patients showed significant improvements across key metrics, including reductions in opening CSF pressure, papilledema (optic nerve swelling), headaches, and visual disturbances, alongside enhanced Quality of Life scores.

“The River Study was groundbreaking as the first-of-its-kind study to evaluate a stent specifically designed for intracranial venous sinuses,” noted Adnan Siddiqui, MD, PhD, a professor of neurosurgery at the Jacobs School of Medicine & Biomedical Sciences and senior author of the study paper. “There is no other stent that is optimized or approved for this indication. The FDA’s review and acceptance of these data will now enable access to this important tool to the broader medical community to treat these patients.”

The device itself is an example of targeted medical engineering. Unlike repurposed peripheral stents, the River stent features a flexible construction with variable radial force and diameter, allowing it to conform to the unique anatomy of the brain's venous sinuses. Its design also incorporates a reduced metal surface area, which is intended to minimize the risk of blood clots, a significant concern in venous stenting.

The regulatory path taken—a Humanitarian Device Exemption—was also strategic. The HDE pathway is designed for devices that treat conditions affecting fewer than 8,000 people in the U.S. annually. It requires the manufacturer to demonstrate a “probable benefit” that outweighs the risks, a standard more attainable for rare conditions where large-scale trials are impractical. This allows crucial innovations for smaller patient populations to reach the market, filling critical gaps in care.

A Strategic Alliance for Market Access

Bringing a breakthrough device from the lab to the patient requires more than just clinical innovation; it demands a robust commercialization strategy. Serenity Medical, a portfolio company of the investment group NeuroTechnology Investors (NTI), has forged a strategic partnership with Radical Technologies to launch the River stent nationwide.

This collaboration leverages the strengths of each entity. Serenity Medical provides the groundbreaking technology, while Radical Technologies brings a specialized neurovascular commercial team with deep experience in launching new devices. This allows Serenity to bypass the time and expense of building a sales force from scratch and instead tap into an established network with relationships at leading neurovascular centers.

The synergy is further enhanced by their shared connection to NTI. Martin Dieck, Chairman of Serenity Medical and a Managing Director at NTI, also serves as Chairman for Radical Catheter Technologies.

“Radical has built a world-class commercialization team with a proven track record of launching breakthrough neurovascular technologies through strategic physician engagement, rigorous clinical education, and hands-on procedural support,” Dieck stated. This integrated approach, combining Radical's industry-leading catheters with innovative solutions from across the NTI portfolio, aims to accelerate market adoption and ensure that this new treatment reaches the patients who have been waiting for it.